Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane

RATIONALE: Within a rapidly expanding therapeutic armamentarium, the combination of everolimus (Eve) plus exemestane (Exe) utility needs to be reinstated in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). PATIENT CONCERNS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasniqi, Eriseld, Barchiesi, Giacomo, Mazzotta, Marco, Pizzuti, Laura, Villa, Alice, Barba, Maddalena, Vici, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402792/
https://www.ncbi.nlm.nih.gov/pubmed/32756099
http://dx.doi.org/10.1097/MD.0000000000021211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402792/
https://www.ncbi.nlm.nih.gov/pubmed/32756099
http://dx.doi.org/10.1097/MD.0000000000021211

Ejemplares similares